Slide 1: Exchange filing cover letter: Investor Presentation Q1FY27
Date: August 12, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSAN
Slide 2: Earnings Presentation Q1 FY27
Earnings Presentation Q1 FY27 12th August 2026 BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 ©2026 – Marksans Pharma Ltd., All Rights Reserved www.marksanspharma.com
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by Marksans Pharma Limited (the “Company”) solely for informational purposes. The information contained herein is not intended to be comprehensive and should not be relied upon as the sole basis for any investment or business decision. This presentatio
Slide 4: Table of Contents
Q1FY27 Financial Business Highlights 01 Q1FY27 Financial & Business Highlights 04 02 Q1FY27 Geographical Highlights 11 Marksans Pharma at a Glance 03 Marksans Pharma at a Glance 18 Table of 04 Marksans’ Journey Marksans’ Journey 24 Contents 05 Strategic Initiatives Strategic Initiatives 30 Sustainab
Slide 5: Q1FY27 Financial & Business Highlights
Q1FY27 Financial & Business Highlights www.marksanspharma.com Page 4
Slide 6: Management Commentary
Management Commentary “Q1FY27 has been a strong start to the year, with an all-time high quarterly EBITDA of ₹213 crore and PAT of ₹159 crore, reflecting the strength of our underlying business and our continued focus on profitable growth. Mark Saldanha UK & Europe delivered their highest-ever quart
Slide 7: Financial Highlights Q1FY27 – YoY Performance
Financial Highlights Q1FY27 – YoY Performance Q1FY27 Q1FY26 YoY Growth YoY Performance Revenue grew 35.6% YoY, with UK & Europe contributing Revenue ₹ 840.8 cr ₹ 620.0 cr 35.6% ₹152 cr, or 69% of the ₹221 cr increase. The US and ANZ contributed ₹50 cr and ₹31 cr, respectively, partly offset by a ₹12
Slide 8: Financial Highlights Q1FY27 – QoQ Performance
Financial Highlights Q1FY27 – QoQ Performance Q1FY27 Q4FY26 QoQ Growth QoQ Performance • Revenue was broadly stable QoQ. Continued Revenue ₹ 840.8 cr ₹ 856.1 cr -1.8% momentum in the UK & Europe added ₹48 crore sequentially, which was offset by seasonal softness in Australia & New Zealand and the US
Slide 9: Financial & Other Highlights – Q1FY27
Financial & Other Highlights – Q1FY27 US & North America UK & Europe Australia & New Zealand Rest of World Revenue by geography ₹377 cr ₹356 cr ₹88 cr ₹20 cr +15.1% YoY +74.7% YoY +53.7% YoY -36.8% YoY Strong cash generation Operating cash flow of ₹185 cr and free cash Net capex of ₹33 cr , with wor
Slide 10: New Corporate Organogram
New Corporate Organogram MARKSANS PHARMA LIMITED India · BSE: 524404 | NSE: MARKSANS | Listed parent US UK EUROPE AUSTRALIA & NZ UAE CANADA NEW NEW Marksans Pharma Inc. Marksans Pharma UK Ltd Marksans Pharma (Europe) Ltd Nova Pharmaceuticals Australasia Access Healthcare for Medical Marksans (Canada
Slide 11: Quarterly Financial Trends
Quarterly Financial Trends Operating Revenue (₹ cr) Gross Profit (₹ cr) & Gross Margin (%) 856 841 497 438 465 754 412 720 358 60.0% 620 57.8% 58.1% 59.1% 57.2% 54.4% 40.0% Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 EBITDA (₹ cr) & EBITDA Margin (%) Net Income (₹ cr) & Net
Slide 12: Q1FY27 Geographical Highlights
Q1FY27 Geographical Highlights www.marksanspharma.com Page 11
Slide 13: Q1FY27 Revenue by Geography
Q1FY27 Revenue by Geography US & North America - ₹ 377 cr UK & Europe - ₹ 356 cr 15% YoY 75% YoY 44.9% 42.3% 2.4% 10.4% RoW - ₹ 20 cr 37% YoY Australia & New Zealand - ₹ 88 cr 54% YoY www.marksanspharma.com Page 12
Slide 14: US & North America Q1FY27 Performance
US & North America Q1FY27 Performance Quarterly Performance (₹ cr) 44.9% 412 406 387 377 328 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Revenue US Overview 15.1% YoY 7.1% QoQ ₹ 377.2 cr • The Company services this region through Time Cap Labs Inc., its wholly owned subsidiary acquired in June 2015 • Leading
Slide 15: UK & Europe Q1FY27 Performance
UK & Europe Q1FY27 Performance UK 42.3% • Strongest quarter for the UK, supported by new launches and continued market-share gains. • UK & Europe, excluding QliniQ, grew 53.1% YoY. Ireland Netherlands • Momentum remains healthy, with a strong order pipeline supporting the outlook. UK • Region servic
Slide 16: Australia & New Zealand Q1FY27 Performance
Australia & New Zealand Q1FY27 Performance Quarterly Performance (₹ cr) 10.4% 123 88 57 61 61 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Revenue Australia & New Zealand Overview 53.7% YoY 29.0% QoQ ₹ 87.6 cr • In 2005, Marksans acquired 60% stake in Nova to have established base in the region • Australia &
Slide 17: Nova Pharmaceuticals — New Prescription Launches in the quarter
Nova Pharmaceuticals — New Prescription Launches in the quarter Nova Pharmaceuticals Australasia Pty Ltd (60% subsidiary) — branded prescription portfolio, Australia Vymaze Prescription Only Medicine Rinidate Controlled Drug · Listed on the PBS Molecule Fluticasone furoate 27.5 mcg per spray Molecul
Slide 18: RoW Business Q1FY27 Performance
RoW Business Q1FY27 Performance Quarterly Performance (₹ cr) 32 27 22 19 20 2.4% Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Revenue RoW Overview 36.8% YoY 6.0% QoQ ₹ 20.0 cr • RoW segment encompasses 10 countries, spanning across CIS and MENA regions • Marksans acquired 100% stake in Access Healthcare in Du
Slide 19: Marksans Pharma at a Glance
Marksans Pharma at a Glance www.marksanspharma.com Page 18
Slide 20: Company Overview
Company Overview ₹ 3,033 cr 20.4% ₹ 1,058cr 4 350+ Total Income FY26 Cash balance 4 Manufacturing Products for FY26 EBITDA Margin (as of 30th Jun 2026) Units & and 2,000+ SKUs 4 R&D Centers ~$175mn Amongst Accreditations 2,000+ in US Top 5 USFDA, UK MHRA, Total Employees Australian TGA, EU and Among
Slide 21: Segmental Revenue
Segmental Revenue Revenue by Segment – FY26 Revenue by Therapeutic Segment – FY26 1,310.8 Rx, 20.0% 460.9 384.0 183.4 171.5 171.5 161.2 54.8 38.4 9.4 5.0 OTC, 80.0% Anti-Allergic Anti-Daibetic Anti -Infectives Gastrointestinal Cardiovascular System(CVS) Anti-cancer supplements (VMS) Anti-hair fall P
Slide 22: Marksans’ OTC Focus
Marksans’ OTC Focus Marksans’ OTC Portfolio Industry Opportunity ❖ According to IQVIA, Global OTC Market size is ❖ The OTC business includes store brands, private projected to be $215 bn in 2026 label manufacturing for retailers and customers ❖ Prescription (Rx) to over-the-counter (OTC) ❖ It also m
Slide 23: Manufacturing Capabilities
Manufacturing Capabilities Manufacturing Facility in Farmingdale, USA Total Capacity : 26 bn units p.a.* • Manufactures hard gels, tablets and capsules • Spread over an area of 7,000 sq. mt. USA • "Made in the USA” product offering • Added incremental packaging lines Manufacturing Facility in Southp
Slide 24: R&D Capabilities
R&D Capabilities R&D (₹ cr) and R&D % to sales 3.0% 2.8% 89 2.2% R&D Southport, 2.0% Farmingdale, United Kingdom 1.5% 1.6% 1.6% United States Navi Mumbai, 1.4% 58 India Goa, India Centers 0.6% 0.6% 0.7% 35 30 29 23 19 15 8 5 5 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Q1FY27 Continued focus
Slide 25: Marksans’ Journey
Marksans’ Journey www.marksanspharma.com Page 24
Slide 26: Our Key Events
Our Key Events • Raised ₹ 372.40 cr in Increased focus on OTC equity via conversion segment in US market OTC Segment’s Spun off into a separate of warrants issued to entity - Glenmark OrbiMed and Revenue crossed ₹ • Acquired Bell, Sons & Promoters 2,000 cr revenue Laboratories Ltd. Co. (Druggists) L
Slide 27: Growth and Achievements Since 2017
Growth and Achievements Since 2017 Operating OTC Revenue Consistent and Consistent Manufacturing SKUs Revenue growth of meaningfully growth in cash capacity growth to growth ~5.3x to high EBITDA from increased from margin operations over 6 bn units p.a. in ~2000+ ~3.8x to ₹ 2,361 cr expansion the ye
Slide 28: Financial Trends – High Growth Trajectory
Financial Trends – High Growth Trajectory Operating Revenue (₹ cr) EBITDA (₹ cr) & EBITDA Margin (%) 3,500.0 2,951 700.0 30.0% 24.7% 20.3% 20.4% 2,623 21.1% 3,000.0 600.0 25.0% 17.4% 2,177 2,500.0 500.0 18.3% 2,000.0 1,852 17.0% 20.0% 1,491 13.2% 400.0 1,376 15.0% 1,500.0 1,134 5.8% 8.6% 601 1,005 3
Slide 29: Financial Trends – High Growth Trajectory
Financial Trends – High Growth Trajectory Total Assets (₹ cr) Net Debt to EBITDA 4,500.0 3,861 2.0x 1.6x 4,000.0 1.0x 1.5x 3,500.0 3,240 0.5x 1.0x 3,000.0 2,681 0.5x 2,500.0 2,190 0.0x 2,000.0 1,640 -0.5x 1,228 -0.4x -0.6x 1,500.0 897 -1.0x 1,000.0 752 732 804 -1.2x -1.3 -1.5x 500.0 -2.0x -1.5x -1.6
Slide 30: Proven Success in Acquisitions
Proven Success in Acquisitions www.marksanspharma.com Page 29
Slide 31: Strategic Initiatives
Strategic Initiatives www.marksanspharma.com Page 30
Slide 32: Core Strategies for Future Growth
Core Strategies for Future Growth To become the most reliable partner in the consumer healthcare space Focus on store brand OTC Segment • Expanding within proven OTC demand areas, expanding market share with customers and key regions. Aim to capture a significant part of the multi-billion-dollar OTC
Slide 33: Capturing OTC Opportunity
Capturing OTC Opportunity Global Category Value Share ($ bn) Expanding OTC Business Value Share Capture multi- • Marksans competes in large and billion-dollar OTC growing categories Others 37 opportunity • Increasing store brand penetration in Skin Treatment 15 Strengthening North America Business i
Slide 34: Product Pipeline
Product Pipeline Continued focus on R&D leading to strong product pipeline and successful launches UK US Australia & New Zealand Rest of the World Canada • 18 products approved • 112 new SKUs • 23 SKUs launched in • Built a strong regulatory • 14 products filed in and 30 filings done in launched in
Slide 35: Key Product Launches in Last 2 Years
Key Product Launches in Last 2 Years Brand COMPOSITION Therapy Segment Market BENZONATATE CAPSULES BENZONATATE CAPSULES USP, 100 mg & 200 mg Cough and Cold US CETIRIZINE DIHYDROCHLORIDE CETIRIZINE DIHYDROCHLORIDE 1 MG/ML ORAL SOLUTION Anti Allergy UK LOPERAMIDE HYDROCHLORIDE LOPERAMIDE HYDROCHLORIDE
Slide 36: Strong Balance Sheet to Drive Inorganic Growth
Strong Balance Sheet to Drive Inorganic Growth Cash balance of ₹ 1,058 cr as of 30th June 2026; net cash of ₹ 1,031 cr Strong credit rating Cash positive for over 5 years. Long term: CARE AA-; Stable | IND AA-; Positive Short term: CARE A1+ | IND A1+ India Ratings revised the outlook to Positive fro
Slide 37: We’ve Delivered What We Promised
We’ve Delivered What We Promised 1 Total Income guidance of ₹ 3,000 cr Achieved 2 Focus on expanding OTC business – ~5.3x revenue growth since 2017 Achieved 3 EBITDA margins in the 18-21% range Achieved 4 Maintain net cash balance sheet Achieved 5 Disciplined capex allocation Achieved www.marksansph
Slide 38: The Marksans Investment Thesis
The Marksans Investment Thesis Scalable Operating Consistent Execution & 01 Structural Shift to OTC 02 Growth Visibility 03 Leverage 04 Financial Strength • Global OTC market reaching $215 bn — • Multiple drivers: launches, categories, • 26 bn unit capacity; Goa Unit 2 doubling • OTC revenue CAGR 20
Slide 39: Growth Roadmap — FY27 and Beyond
Growth Roadmap — FY27 and Beyond Marksans Growth Algorithm FY27–28 Milestones Strategic Vision FY30 ● India capacity: 16 bn units ● Top global consumer p.a. healthcare company DEEPEN • Increase SKUs per existing retailer ● Expand US and North ● Multi-continent front-end • Expand share in core OTC ca
Slide 40: Sustainability at Marksans
Sustainability at Marksans www.marksanspharma.com Page 39
Slide 41: Driving Sustainable Progress
Driving Sustainable Progress Environment Social Governance Ensure sustainability in our Positively impact our people Bring about an industry operations and projects by and community through utmost transformation by leading ethically positively impacting the natural respect for human rights, and bols
Slide 42: Empowering Communities
Empowering Communities 01 02 03 04 05 Health Care Education Environment Food Distribution Overall wellbeing of women • Organized free health • Contribution towards • Building and upkeep of • Distribution of free and children check-up camps and education of public gardens/parks food items to daily •
Slide 43: Environmental Sustainability Initiatives
Environmental Sustainability Initiatives Improving operational and manufacturing efficiency and attract environmentally conscious value chain partners and focusing on optimum use of natural resources and raw materials Increased use of recycled packaging materials by over 400%. Plan underway for usin
Slide 44: Corporate Governance Standards
Corporate Governance Standards A strong ethical organization with a focus on Has stringent codes of conduct and transparency, accountability, adequate policies in place for observance by disclosure and compliance directors, employees, and workers Robust risk management framework for proactive Has in
Slide 45: Board of Directors - Guided By Visionary Minds
Board of Directors - Guided By Visionary Minds Mark Saldanha Sandra Saldanha Varddhman Jain Dr. Sunny Sharma Founder, Chairman & Promoter, Whole-Time Director Non-Executive Director Managing Director Whole-Time Director • Science Graduate • MA in Arts (Sociology) • M. Pharm (Pharmaceuticals) • MBA,
Slide 46: Board of Directors - Guided By Visionary Minds
Board of Directors - Guided By Visionary Minds Abhinna Sundar Mohanty Digant Mahesh Parikh Shailaja Vardhan Mr. Srinivas Mishra Independent Director Independent Director Independent Director Independent Director • M.Sc., Mathematics • MBA, Finance • Seasoned professional in • B. Sc Hons (Mathematics
Slide 47: Experienced Leadership Team
Experienced Leadership Team Mark Saldanha Varddhman Jain Sathish Kumar Anjani Kumar David Mohammed Jitendra M Sharma Founder, Chairman & Whole-Time Director MD – Marksans Pharma COO – Global Operations MD – Nova Pharmaceuticals Chief Financial Officer Managing Director UK Ltd. and USA Australasia Pt
Slide 48: Annexure
Annexure www.marksanspharma.com Page 47
Slide 49: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (₹ cr.) Q1FY27 Q1FY26 Q4FY26 YoY QoQ Operating Revenue 840.8 620.0 856.1 35.6% -1.8% Gross Profit 497.3 358.2 465.5 38.9% 6.8% Gross Margin % 59.1% 57.8% 54.4% 138 bps 478 bps EBITDA 213.0 100.1 195.4 112.8% 9.0% EBITDA Margin % 25.3% 16.1% 22.8% 919
Slide 50: Shareholding Pattern — As of June 2026
Shareholding Pattern — As of June 2026 Shareholding — Q1FY27 (Jun 2026) Shareholding Trend – Q1FY27 Category Q1FY27 Promoters (%) 43.9 32.5% 43.9% FII / FPI (%) 17.5 of which OrbiMed (%) 8.6 6.2% 8.9% 8.6% DII (%) 6.2 Public & Others (%) 32.5 Promoters OrbiMed (foreign) Other FII/FPI Source: BSE DII
Slide 51: Thank You
Thank You For more information please contact: Jitendra Sharma (CFO) Corporate Office Marksans Pharma Ltd. 11th Floor Grandeur, Off Veera Desai Road, Tel: +91 22 4001-2000 jitendra@marksanspharma.com Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India © 2026 Marksans Pharma Ltd